Brief: Actinium Pharmaceuticals, Immedica Announce Commercialization Agreement For Iomab-B
12/04/2022 12:31
April 12 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS, INC. AND IMMEDICA ANNOUNCE
COMMERCIALIZATION AGREEMENT FOR IOMAB-B (131I APAMISTAMAB) IN
EUROPE, THE MIDDLE EAST AND NORTH AFRICA
* ACTINIUM PHARMACEUTICALS INC - ACTINIUM RECEIVES $35
MILLION
UPFRONT PAYMENT
* ACTINIUM PHARMACEUTICALS INC - IMMEDICA OBTAINS EXCLUSIVE
RIGHTS
TO IOMAB-B IN EUROPE, MIDDLE EAST AND NORTH AFRICA
* ACTINIUM PHARMACEUTICALS INC - CO WILL BE ELIGIBLE TO
RECEIVE AN
ADDITIONAL $417 MILLION IN REGULATORY AND COMMERCIAL MILESTONES
* ACTINIUM PHARMACEUTICALS INC - CO WILL BE ELIGIBLE TO
RECEIVE
ROYALTIES IN MID-TWENTY PERCENT RANGE ON NET SALES
Source text for Eikon: ID:nPnncR8Ba
Further company coverage: ATNM.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals Announces Actimab-A Intellectual Property And Manufacturing Advances And Provides NYSE American Listing Update
Brief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225